SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 16, 2004
RESPIRONICS, INC.
(Exact name of Registrant as specified in its charter)
| Delaware | 000-16723 | 25-1304989 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (I.R.S. Employer Identification Number) | ||
| 1010 Murry Ridge Lane Murrysville, Pennsylvania |
15668-8525 | |||
| (Address of Principal Executive Offices) | (Zip Code) | |||
724-387-5200
(Registrant’s telephone number, including area code)
| Page | ||
| 2 | ||
| 3 | ||
| 4 | ||
Item 9. REGULATION FD DISCLOSURE.
The following information is furnished pursuant to Item 12, “Disclosure of Results of Operations and Financial Condition.”
On January 16, 2004, Respironics, Inc. issued a press release announcing that it has signed a Purchasing Agreement Amendment with Apria Healthcare Group Inc. to extend the Company’s relationship through December 31, 2004. In that press release, Respironics, Inc. also reported that it will not be changing its financial outlook or guidance for fiscal year 2004 and fiscal year 2005. A copy of the press release is attached hereto as Exhibit 99.
| Exhibits |
||
| 99 | Press release, dated January 16, 2004, issued by Respironics, Inc. |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| RESPIRONICS, INC. | ||||
| By: |
/s/ Daniel J. Bevevino | |||
| Daniel J. Bevevino | ||||
| Vice President, and Chief Financial and Principal Accounting Officer | ||||
Dated: January 16, 2004
3
| Exhibit No. |
Description | |
| 99 | Press release, dated January 16, 2004, issued by Respironics, Inc. |
4